Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Morgan Wallen announces 'Still the Problem' 2026 stadium tour, highlighting his continued commercial success despite past controversies.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Morgan Wallen announces 'Still the Problem' 2026 stadium tour, highlighting his continued commercial success despite past controversies.